Lv31
370 积分 2023-03-01 加入
SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study
1个月前
已完结
Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial
1个月前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence
1个月前
已完结
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
1个月前
已完结
In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y
1个月前
已完结
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
1个月前
已完结
Morphology and fracture behavior of lithium disilicate dental crowns designed by human and knowledge-based AI
1个月前
已关闭
Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial
1个月前
已完结
皖公网安备34019202002308
